Immune Checkpoint Inhibitors Market Research and Clinical Analysis 2017 to 2027
Cancer is the leading cause of death worldwide and hence offers a lot of unmet research areas yet to be targeted. The field of oncology is wide comprising a varied type of application area. The focus of researchers is gradually shifting towards the immunotherapies. The immunotherapy makes the use of body’s own components to fight cancer. Immune checkpoints are molecules that stimulate or inhibit the immune cells. Yervoy was the first drug launched in the immune checkpoint inhibitors domain. This anit-CTLA-4 drug was followed by many other drugs such as Keytruda and Opdivo. Besides these molecules there are several others under clinical development. There is an ongoing competition between the immune checkpoint inhibitors market contributors to emerge as a leader.
Immune Checkpoint Inhibitors Market: Drivers and Restraints
The immune checkpoint inhibitors market is driven by the number of research developments undertaken by industry contributors as well as academic institutes. The immune checkpoint inhibitors market is experiencing a lot of collaborations wherein companies are combining their core competencies to fasten their research programs. For instance, Merck known as MSD outside the U.S. and Canada along with Dynavax Technologies Corporation are investigating the potential synergistic effects by combining Dynavax’s SD-101 with two of Merck’s immunotherapies Keytruda and MK-1966.
A Sample of This Report Is Available Upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3326
Immune Checkpoint Inhibitors Market: Segmentation
Immune checkpoint inhibitors market is classified on the basis of drug targets, application and region.
Based on drug targets the immune checkpoint inhibitors market is segmented into the following:
- PD-1 inhibitors
- PD-L1 inhibitors
- Chimeric Antigen Receptor T-cell (CAR-T)
Monoclonal antibodies that target either PD-L1 or PD-1 can block its binding to the cells and boost immune response against cancer cells. There are many clinical trials in pipeline where in drugs that targets either PD-1 inhibitors or PD-L1 inhibitors are tested alone or in combination with other drugs.
Based on application the immune checkpoint inhibitors market is segmented into the following:
- Lung cancer
- Renal cancer
- Blood cancer
- Bladder cancer
- Hodgkin lymphoma
Immune Checkpoint Inhibitors Market: Overview
The immune checkpoint inhibitor market is driven by the need to address the rising rate of cancer prevalence thereby affecting the country healthcare cost. In UK, lung cancer is the leading cause of cancer related death. The survival rate past five years has only being 9% after the person is diagnosed with lung cancer. The new form of immunotherapy based on the inhibition of programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) receptors has shown hope as a therapy option for lung cancer.
Immune Checkpoint Inhibitors Market: Region-wise Outlook
In terms of geography, immune checkpoint inhibitors market has been divided into five regions including North- America, Asia- Pacific and Middle-East & Africa, Latin America and Europe. The number of clinical trials and research funding is relatively high in North America, making it the dominant region in terms of revenue in the immune checkpoint inhibitors market. In September 2014, Merck received accelerated FDA approval for its Keytruda molecule to treat patient with advanced melanoma. The company is forming global alliances with other companies to co-develop
immnuo-oncology research and expand its oncology business.
Asia Pacific is the fastest growing region in the immune checkpoint inhibitors market as there are number of research collaborations of international players with companies from this region. For instance, Bristol-Myers Squibb received Japanese approval for Opdivo in 2014, through partnership with Ono Pharmaceuticals.
Request Complete TOC of this Report @https://www.futuremarketinsights.com/toc/rep-gb-3326
Immune Checkpoint Inhibitors Market: Key Market Participants
Some of the market contributors to the immune checkpoint inhibitors market are Bristol-Myers Squibb, Merck & Co., Inc., Roche, AstraZeneca, Merck KGaA, Ono Pharmaceutical Co., Ltd., Novartis International AG, Juno Therapeutics and Kite Pharma.
There is intense competition in the immune checkpoint inhibitors market which is driving acquisitions and in-licensing agreements. The major immune checkpoint inhibitors market participants are striving to expand and diversify their product pipeline. Moreover, companies are forming alliances to synergize their programs to develop combination therapies. There are number of small players who are trying to explore the potential of immune checkpoint inhibitors market by developing next generation immune checkpoint inhibitors therapy.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/toc/rep-gb-3326
The report covers exhaust analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
Regional analysis includes:
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain)
- Eastern Europe (Poland, Russia)
- Asia Pacific (China, India, ASEAN, Australia & New Zealand)
- Middle East and Africa (GCC Countries, S. Africa, Northern Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
- Detailed overview of parent market
- Changing market dynamics of the industry
- In-depth market segmentation
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
- Must-have information for market players to sustain and enhance their market footprint
Get full Report Now@ https://www.futuremarketinsights.com/checkout/3326
About Us – Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.
Future Market Insights
616 Corporate Way,
New York 10989,